Jane Street Group LLC Sells 9,090 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Jane Street Group LLC reduced its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 40.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,300 shares of the medical device company's stock after selling 9,090 shares during the quarter. Jane Street Group LLC's holdings in AtriCure were worth $406,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Adage Capital Partners GP L.L.C. acquired a new position in AtriCure in the fourth quarter valued at about $9,168,000. Kennedy Capital Management LLC raised its position in shares of AtriCure by 29.8% during the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after purchasing an additional 172,648 shares during the period. Marshall Wace LLP lifted its holdings in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after purchasing an additional 167,476 shares in the last quarter. Oberweis Asset Management Inc. acquired a new position in shares of AtriCure in the 4th quarter valued at approximately $4,630,000. Finally, Dimensional Fund Advisors LP increased its stake in AtriCure by 24.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock worth $21,398,000 after purchasing an additional 136,015 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total transaction of $83,600.00. Following the transaction, the insider now owns 73,550 shares in the company, valued at approximately $2,459,512. This trade represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.50% of the company's stock.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded up $0.19 on Wednesday, hitting $34.92. The company had a trading volume of 497,787 shares, compared to its average volume of 649,713. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -36.76 and a beta of 1.57. The stock has a 50 day moving average price of $32.31 and a 200 day moving average price of $34.67. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. The business had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. AtriCure's revenue was up 13.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) EPS. Analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ATRC shares. Stifel Nicolaus lifted their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Piper Sandler raised their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. BTIG Research reaffirmed a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. JPMorgan Chase & Co. reduced their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. Finally, Needham & Company LLC decreased their price objective on AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, AtriCure currently has an average rating of "Moderate Buy" and an average target price of $50.67.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.